Timeframe: 2012 – 2014
Goal: Assess potential of treatment options for FLC
Principal Investigator: Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center
FCF funded the first clinical trial of drugs aimed specifically at fibrolamellar liver cancer. The trial was also conducted at other consortium members, including the University of California San Francisco, Johns Hopkins, and Dana Farber. Two major pharmaceutical companies donated the drugs.
Key findings: Estrogen deprivation therapy with letrozole and leuprolide, alone or in combination with the mTOR inhibitor, everolimus, did not demonstrate clinical activity in advanced fibrolamellar carcinoma.
Click here to read the published results of the study.